Format

Send to

Choose Destination
J Hepatocell Carcinoma. 2018 Oct 3;5:87-90. doi: 10.2147/JHC.S171396. eCollection 2018.

Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI).

Author information

1
Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil, victorhugoba@gmail.com.

Abstract

At the 2018 Gastrointestinal Cancer Symposium, sponsored by the American Society of Clinical Oncology, significant advances in the management of hepatocellular carcinoma (HCC) were announced. In intermediate-stage disease (Barcelona Clinic Liver Cancer stage B), interest in combining transarterial chemoembolization and sorafenib has been reignited as a consequence of the TACTICS trial. In advanced-stage disease (BCLC C), external-beam radiotherapy combined with transarterial chemoembolization proved to be superior to sorafenib in patients with portal vein thrombosis according to the START trial. Also, in patients with advanced-stage HCC, the CELESTIAL trial demonstrated survival benefits for patients undergoing treatment with cabozantinib in the second-line setting. Lastly, recent data on the activity of pembrolizumab in patients with HCC highlight the role of immunotherapy in the management of this disease in the years to come.

KEYWORDS:

ASCO; cancer; carcinoma; hepatocellular; highlights; liver; meeting

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center